Document is current

Article History

Received: 30 October 2025

Accepted: 27 November 2025

First Online: 6 December 2025

Declarations

:

: Azmeralda Abraheem has received funding to support conference attendance from Novartis. Neenu Sebastian has received funding to support conference attendance from AbbVie and Novartis. Tim H Clayton have no conflicts of interest. Firas C Kreeshan has been a speaker for AbbVie, Almirall, Janssen, Leo pharma, Eli Lilly, Sanofi and UCB; received honoraria and/or consultancy fee and/or travel bursaries and/or Educational grants have been from: Abbvie, Almirall, Galderma, Janssen, Leo pharma, Eli Lilly, Sanofi and UCB; and been an investigator (Sub-I) for Abbvie, Jansen and Eli Lilly. Hamish JA Hunter has received grant funding from AbbVie, Pfizer, Janssen and Merck Serono; honoraria and/or consultancy fees and/or travel bursaries from La Roche-Posay, Janssen, Abbvie, UCB, Sanofi Genzyme, Regeneron, Novartis, Almirall, Leo, Eli Lilly DICE Therapeutics, UNION Therapeutics, Pfizer and Galderma and has acted as an investigator for Janssen, Abbvie, UCB, Sanofi Genzyme, Novartis, Almirall, Leo, Eli Lilly, DICE Therapeutics, UNION Therapeutics, Evelo Biosciences Inc., ONO Pharmaceutical Co. Ltd. Bayer Pharmaceuticals, Artax Biopharma, Sudo Biosciences and No7 Beauty Company. Richard B Warren has acted as a consultant and/or speaker for and/or received research grants from AbbVie, Amgen, Almirall, Celgene, Eli Lilly, Pfizer, LEO Pharma, Novartis, Janssen Cilag, Medac, UCB Pharma and Xenoport. Richard B Warren is an Editor-in-Chief of Dermatology and Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: The data presented was captured in routine clinical care assessing the safety and efficacy of patients using a new therapy in our centre. Additional ethics approval is not required.